NCT02387151View on ClinicalTrials.gov

Allogeneic Mesenchymal Stromal Cell Therapy in Renal Transplant Recipients

PHASE1CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

March 31, 2015

Primary Completion Date

November 30, 2018

Study Completion Date

November 30, 2018

Conditions
RejectionGraft Loss
Interventions
DRUG

mesenchymal stromal cells

2 doses of 1-2x10\^6 allogeneic bone marrow derives MSCs IV per/kg body weight at weeks 25 and 26 after transplantation

Trial Locations (1)

2333 ZA

Leiden University Medical Center, Leiden

All Listed Sponsors
lead

Leiden University Medical Center

OTHER

NCT02387151 - Allogeneic Mesenchymal Stromal Cell Therapy in Renal Transplant Recipients | Biotech Hunter | Biotech Hunter